AA
LBRX

ALPS Advisors’s LB Pharmaceuticals LBRX Stock Holding History

ALPS Advisors’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$945K Buy
+29,102
New +$855K ﹤0.01% 714

Other funds holding LBRX

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MHC
Meyer Handelman Company Rye Brook, New York $3.53B AUM 30.49% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

ALPS Advisors's LBRX Position: Q2 2026 in Review

ALPS Advisors opened a new position in LB Pharmaceuticals (LBRX) in Q2 2026: 29,102 shares worth $945K. The stake represents ﹤0.01% of the portfolio and ranks #714 among its holdings.

13 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • ALPS Advisors held 29,102 shares of LB Pharmaceuticals worth $945K as of Q2 2026.
  • LB Pharmaceuticals was a new ALPS Advisors position in Q2 2026.
  • LB Pharmaceuticals made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #714 holding.
  • 13 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.